Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions

New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce

NATCO launches Everolimus tablets, 1 mg

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

RestorixHealth acquires CutisCare to expands wound care portfolio

MedCognetics and Laurel Bridge unite to revolutionize breast cancer screening with secure AI workflow

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025

Granules India’s facility secures FDA EIR with 'VAI’

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025